Treatment of multidrug-resistant tuberculosis in a high-prevalence region through a binational consortium

Int J Tuberc Lung Dis. 2012 May;16(5):610-1. doi: 10.5588/ijtld.11.0544. Epub 2012 Mar 7.

Abstract

We describe the outcome of treatment of multidrug-resistant tuberculosis (MDR-TB) in Baja California, Mexico, by a United States-Mexico consortium. From June 2006 to December 2010, 42 patients started treatment. Strains were resistant to 4.15 ± 1.3 drugs; all patients achieved culture conversion on treatment after an average of 3.4 ± 1.6 months. A total of 19 patients (47.5%) were discharged as cured, 3 died (7.5%) and 1 defaulted (2.5%). MDR-TB cases can be cured under a well-organized out-patient program; in this consortium, the US partner introduced program elements that were gradually integrated into the Mexican state TB program.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use*
  • Female
  • Humans
  • International Cooperation
  • Male
  • Mexico / epidemiology
  • Microbial Sensitivity Tests
  • Middle Aged
  • National Health Programs / organization & administration*
  • Prevalence
  • Program Development
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / microbiology
  • United States
  • Young Adult

Substances

  • Antitubercular Agents